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Abstract
Burden of Chronic Obstructive Pulmonary Disease (COPD) is substantial and increasing in 
the world. There are controversial reports regarding vitamin D supplementation in COPD. We 
investigated relationship between vitamin D3 (Cholecalciferol) supplementation with Health 
Related Quality of Life (HRQOL) and symptom recovery in AECOPD patients with concurrent 
Vitamin D Deficiency (VDD). A placebo-controlled randomized clinical trial was designed. 
AECOPD patients with VDD were randomly allocated to receive either vitamin D 300,000 IU 
(n = 35) or placebo (n = 35) by intramuscular injection. Primary outcomes included the HRQOL 
assessed by St. Georgeʹs Respiratory Questionnaire (SGRQ), and the symptom recovery 
evaluated by the modified Medical Research Council (mMRC) Dyspnea scale, determined at 
baseline and at days 30 and 120 post-intervention. Secondary endpoints were length of hospital 
stay (LOS), rehospitalization and mortality rates.
Sixty-two patients, 30 patients in the vitamin D and 32 patients in the placebo groups, with 
mean ± SD age of8.48 ± 63.42  years accomplished the study. Baseline vitamin D levels in 
the vitamin D and placebo groups were 10.59 ± 3.39 and 11.12 ± 3.17 ng/mL, respectively. 
These levels reached 36.85 ± 11.80 and 12.30 ± 3.66 in the vitamin D and placebo groups, 
respectively, at day 120 (p < 0.001). Correction of vitamin D levels in the intervention group 
resulted in statistically significant improvement in patients’ HRQOL by day 120 compared to 
that of the placebo group (p = 0.001); however no significant difference was observed in LOS, 
rehospitalization, and mortality rates. Single parenteral high dose of vitamin D as adjunctive 
therapy could improve HRQOL in hospitalized AECOPD patients with deficient levels of 
vitamin D. 
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Introduction Chronic Obstructive Pulmonary Disease 
(COPD) was known as the third leading cause of 
death in the world and had resulted in over 3.1 
million deaths globally in 2012 (1). In addition, 
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prevalence and burden of COPD is risen over 
time (2). Majority of this burden is attributed to 
hospitalization and disease exacerbations (3). 
COPD bares a substantial burden for patients, 
family, and the health care system (4). Patients 
with COPD had significantly worse activities of 
daily living and physical, social, and emotional 
functioning than the patients with non-small cell 
lung cancer (5) and Quality of life is significantly 
impaired in COPD patients (5-7), even in those 
with mild airway obstruction (8). Vitamin D 
Deficiency (VDD) as global health problem was 
shown to be a modifiable explanatory factor to 
improve outcomes in several chronic diseases 
(9). In a recent meta-analysis on COPD patients, 
high prevalence of VDD was reported, especially 
during disease exacerbation (10). VDD was 
associated with disease severity, poor quality 
of life, reduced lung function, longer hospital 
stay, frequent exacerbations, hospitalization, 
reduced physical functioning, poor balance and 
less muscle strength in COPD patients (10-13). 
Key role of vitamin D in inflammation process 
and COPD associate comorbidities including 
respiratory infection, cardiovascular  disease, 
skeletal muscle dysfunction, depression and 
anxiety (14-18) as well as vitamin D role in 
enhancement of patients’ response to steroid 
therapy (19), open an interesting field to explore 
effects of the vitamin D on clinical outcomes 
such as HRQOL and dyspnea scale in AECOPD 
patients. 
Data regarding vitamin D supplementation 
in COPD is still controversial but promising 
(20). Although, some studies have shown no 
significant improvement in clinical outcomes 
such as dyspnea severity (21), physical 
performance (22), quality of life (23), and lung 
function of COPD patients receiving vitamin D 
supplement (22, 24), several studies revealed 
that vitamin D supplementation could improve 
lung function (25), reduce exacerbation rates (25, 
26), improve in inspiratory muscle strength and 
maximal oxygen uptake (27), and also improve 
dyspnea scale, physical performance, maximum 
voluntary ventilation and maximal inspiratory 
pressure (28). In this study, we assessed effect 
of rapid normalization of vitamin D levels, using 
recommended high dose intramuscular vitamin 
D injection (29), on clinical outcomes including 
HRQOL, symptom recovery (dyspnea scale), 
length of hospital stay (LOS), mortality rate, and 
rehospitalization, in patients hospitalized with 
AECOPD.
Experimental
Study design and patients
The study was designed as a randomized 
double-blind placebo-controlled trial, conducted 
at the Masih Daneshvari, a referral teaching 
hospital in Shahid Beheshti University of 
Medical Sciences, Tehran, Iran, from December 
2015 to October 2016. The study was registered 
at the Iranian Clinical Trial Registry (IRCT 
2016031425726N4) and approved by the 
University Ethics Committee (IR.SBMU.
PHNM.1394.306). 
Estimated sample size for each study group 
was 28 patients, with α = 0.05 and power = 80%. 
Considering 20% dropout in the patients allocated 
in the study groups, total number of 70 patients 
(35 patients in each group) with COPD stages 
II-IV according to Global initiative for chronic 
Obstructive Lung Disease (GOLD) report 2015 
(post-bronchodilator FEV1–FVC ratio 0.7, and 
had an FEV1 less than 80% predicted) entered 
the study. The participants were included if 
they admitted the diagnostic of AECOPD in the 
emergency ward and meet the inclusion criteria 
as below: Vitamin D deficiency (serum 25(OH)D 
< 20 ng/mL), age ≥ 40 years. Exclusion criteria 
included: serum 25(OH)D < 5 ng/mL, vitamin D 
supplementation within six month prior to study, 
use of maintenance dose of oral corticosteroids 
within three months prior to study, diagnosed 
asthma, osteoporosis, renal failure (serum 
createnine ≥ 2.5 mg/dL), nephrolithiasis, 
uncompensated liver failure (Child-pugh class 
B, C), hypercalcemia (ionized calcium > 1.3 
mmol/L), conditions associated with pathological 
1-alpha hydroxylase activity such as sarcoidosis, 
lymphoma or multiple myeloma, coagulopathy 
(platelet count < 30,000 per mm3 or international 
normalized ratio > 3),  contraindication for 
intramuscular administration, pregnancy, 
lactation, and immuno-compromised patients 
e.g. patients on chemotherapy or transplant 
patients. Informed consent was obtained 
from all participants before their enrollment.
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Randomization and treatment design
The permuted (balanced) block randomization 
was used for treatment allocation in this trial. 
The patients were randomly allocated to 
receive vitamin D3 (Cholecalciferol) 300,000 
IU (Daropakhsh-Iran) or placebo as a single 
intramuscular injection. The patients in both 
groups were on standard treatment for AECOPD 
according to GOLD report 2015. Standard 
treatment included: [1] short-acting inhaled 
beta2-agonists with or without short-acting 
anticholinergics, [2] A dose of 40 mg prednisone 
per day for 5 days or nebulizer budesonide, 
[3] Antibiotics for patients with three cardinal 
symptoms (increase in dyspnea, sputum volume, 
and sputum purulence), or those who have two 
of the cardinal symptoms, if increased purulence 
of sputum is one of the two symptoms or require 
mechanical ventilation, for 5-10 days (18). 
Study outcomes
Primary outcomes included HRQOL of the 
patients, which was assessed by St. Georgeʹs 
Respiratory Questionnaire (SGRQ), and 
symptom recovery which was evaluated by the 
modified Medical Research Council (mMRC) 
dyspnea scale. Furthermore, the secondary  end 
points were lengths of hospital stay (LOS), 
rehospitalization, and mortality rates during 
120-day of study period.
Measurements and follow-up
Data regarding SGRQ and mMRC scores 
were collected at three different points in time: 
at baseline and follow up at day 30 and day 120 
post-intervention. 
The SGRQ is the most comprehensive 
disease specific health related quality of life 
questionnaire (HRQOL) designed to measure 
and quantify health-related health status in 
patients with chronic airflow limitation (18). 
SGRQ evaluates symptoms, activities, and 
the impact of  the disease on daily life of the 
patients. Scores range from 0 to 100 (maximum 
impairment) and decrease of at least four points 
in the total score of the SGRQ was defined as a 
clinically significant improvement in quality of 
life (30).
The modified Medical Research Council 
(mMRC) scale was used to assess the severity 
of patientʹs dyspnea. Dyspnea as cardinal 
symptom of COPD is a major cause of disability 
and anxiety associated with the COPD. mMRC 
Score ranges from 0 to 4, with higher scores, 
indicating more severe dyspnea (18).
Detailed data about medical history which 
were recommended by GOLD guideline 
including patient exposure to risk factors such 
as smoking, occupational or environmental 
exposure, past medical history, history of 
exacerbation and previous hospitalization for 
respiratory disorder, presence of comorbidity, 
demographic data, and relevant para-clinic or 
laboratory finding were also collected for further 
analysis.
Statistical analysis
Data analysis was conducted with IBM SPSS 
Statistics v 21.0 software. Continuous variables 
were assessed for normality by “Kolmogorov-
Smirnov” test, and according to its results, t-test 
(normal distribution) or Mann–Whitney U-test 
(non-normal distribution) was used for between 
groupʹs comparisons. Continuous variables 
expressed as mean ± Standard Deviation 
(SD) or median (interquartile range) where 
appropriate. Categorical and nominal variables 
were expressed as frequency (%) and were 
analyzed using Chi-square test or Fisher’s-exact 
test. Repeated measure analysis was also used 
to compare vitamin D effect on patient HRQOL 
(SGRQ) and dyspnea severity (mMRC). Pearson 
or Kendellʹs Rank correlations were applied to 
assess the association between vitamin D at 
baseline and clinical finding. P-values < 0.05 
were considered statistically significant.
Results 
Patients’ characteristics
Out of 213 patients assessed for eligibility, 
85 patients met the primary criteria. They were 
assessed for vitamin D level. Six patients with 
serum levels of 25(OH)D < 5 ng/mL and 9 
patients with serum levels of 25(OH)D > 20 ng/
mL were excluded from the study. Therefore, 70 
patients with VDD were allocated equally in the 
study groups. Finally, 30 patients in the vitamin 
D group and 32 patients in the placebo group 
accomplished the clinical trial (Figure 1).
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The baseline characteristics of the 62 patients 
included in the placebo and vitamin D groups 
are shown in Table 1. There was no statistically 
significant difference in baseline variables 
between vitamin D and placebo groups (p > 
0.05).
Change in vitamin D levels
At baseline, mean ± SD of serum 25(OH)
D levels were 10.59 ± 3.39 ng/mL and 11.12 ± 
3.17 ng/mL in vitamin D and placebo groups 
respectively and did not differ in between 
groups comparison (p = 0.82). Vitamin D 
supplementation resulted in a statistically 
significant increase in serum 25(OH)D levels in 
vitamin D group (36.85 ± 11.80 ng/mL) versus 
placebo group (12.30 ± 3.66 ng/mL), by day 120 
[p = 0.000, (CI -30.0, -18.90)].
Primary outcomes 
Changes in HRQOL (SGRQ)
Baseline SGRQ scores included symptom, 
activity, impact and total scores were not 
statistically different  in between group’s 
comparison (Table 2). Mean ± SD of the 
differences between baseline and the 30th and 
120th days of SGRQ scores and its components 
are presented in Table 2.
Mean ± SD differences between baseline and 
day 30 of SGRQ total score were 3.73 ± 1.84 
and 5.69 ± 2.13 units for placebo and vitamin 
D groups, respectively. Since mean difference of 
1.96 in between groups, was less than 4 units, 
improvement in HRQOL in vitamin D group 
was not considered clinically significant, by day 
30. However, between groups comparison of the 
differences of the SGRQ total scores at baseline 
and day 30, revealed a statistically significant 
variation [p = 0.0003, (CI -2.96, -0.94)].
Mean ± SD differences between baseline and 
day 120 of SGRQ total score were 3.99 ± 2.19 
and 8.66 ± 3.32 for the placebo and vitamin D 
groups, respectively. Since mean difference of 
4.67 in between groups, exceeded the minimum 
clinically important difference of 4 units (30), 
the improvement in HRQOL in vitamin D 
group was considered clinically significant, 
by day 120. Between group comparison of the 
differences of the SGRQ total scores at baseline 
and day 120, showed a statistically significant 
difference between two groups [p = 0.0001, (CI 
-6.11, -3.23)].
Repeated measures analysis of variance, 
showed statistically significant improvement in 
SGRQ total scores in vitamin D group compared 
with the placebo (F (1.74, 109.41) = 33.56, p < 
0.001). 
Changes in Dyspnea Severity Scale (mMRC)
The mMRC scores at baseline in placebo and 
vitamin D groups were not statistically different 
(p = 0.31) (Table 1). By day 30 change in 
mMRC scores were 0.97 ± 0.78 and 1.13 ± 0.82 
in placebo and vitamin D groups respectively 
Figure 1. Study flowchart.
were expressed as frequency (%) and were analyzed using Chi-square test or Fisher’s-exact 
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Results  
Patients’ characteristics 
Out of 213 patients assessed for eligibility, 85 patients met the primary criteria. They were 
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Table 1. Baseline characteristics of the patients.
p-valueVitamin D group (n = 30)Placebo group (n = 32)Variable
0.54*62.73 ± 8.26*64.06 ± 8.77Age (year)
0.91
Male: 25 (83.33%)Male: 27 (84.38%)
Gender
Female: 5 (16.67%)Female: 5 (15.62%)
0.80
No: 5 (16.67%)No: 6 (18.75%)
Education
Elementary: 17 (56.67%)Elementary: 16 (50%)
High school: 6 (20%)High school: 9 (28.13%)
Academic: 2 (6, 67%)Academic: 1 (3.12%)
0.36
Unmarried: 0 (0%)Unmarried: 2 (6.25%)
Marital status Married: 25 (83.33%)Married: 24 (75%)
Divorced, widowed: 5 
(16.67%)
Divorced, widowed: 6 
(18.75%)
0.81
Low: 6 (20%)Low: 6 (18.75%)
Income
Middle: 13 (43.33%)Middle: 17 (53.13%)
Upper middle: 6 (30%)Upper middle: 4 (12.5%)
High: 2 (6.67%)High: 3 (9.38%)
0.85*22.99 ± 1.69*22.90 ± 1.97BMI (kg/m²)
0.42**50 (40, 50)**50 (40, 58)Smocking (pack/year)
0.6512 (40%)11 (34.38%)Water pipe use
0.89
Ex-smokers: 23 (76.66%)Ex-smokers: 25 (78.13%)
Smoking status
Current smokers: 7 (23.33%)Current smokers: 7 (21.88%)
0.87
II: 13 (40.63%)II: 16 (50%)
COPD Stage III: 12 (40%)III: 11 (34.38%)
IV: 5 (16.67%)IV: 5 (15.63%)
0.86
Moderate: 10 (33.33%)Moderate: 10 (31.25%)
AECOPD Severity
Severe: 20 (66.67%)Severe: 22 (68.75%)
0.61
< 3 times/year: 14 (46.67%)< 3 times/year: 17 (53.13%)
Exacerbation History
≥ 3 times/year: 16 (53.33%)≥ 3 times/year: 15 (46.87%)
0.16Hypertension: 8 (26.67%)Hypertension: 14 (43.75%)
Presence of co-morbidities
0.59Diabetes: 3 (10%)Diabetes: 2 (6.25%)
0.46Depression/Anxiety: 6 (20%)Depression/Anxiety: 9 
(18.75%)
0.64IHD: 5 (16.67%)IHD: 4 (12.50%)
0.59Stroke: 1 (3.33%)Stroke: 2 (6.25%)
0.93HF: 3 (10.00%)HF: 4 (12.5%)
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(p = 0.44). By day 120, the change in mMRC 
scores were 1 ± 0.76 and 1.27 ± 0.78 in placebo 
and vitamin D groups respectively (p = 0.17). 
There is no statistically significant difference in 
between group comparison. Change in mMRC 
score during study period in vitamin D and 
placebo groups was showed in Figure 2. 
Repeated measures analysis of variance, 
showed statistically non-significant changes in 
mMRC scores in vitamin D group compared to 
the placebo (F (2.05, 127.01) = 0.76, p = 0.48). 
Secondary outcomes 
The mean ± SD and [Median (interquartile 
range)] length of hospital stay was 8.06 ± 3.46, 
[7 (6.91, 9.20)], 7.37 ± 2.59, and [7 (6.53, 
8.55)] days in placebo and vitamin D groups, 
respectively, which did not differ significantly 
in between group comparison [p = 0.36]. 
Rehospitalization rates during the study period 
were 48.57% (n = 17) and 37.14% (n = 13) in 
the placebo and vitamin D groups, respectively 
(p = 0.33). Mortality was reported in 2 and 3 
patients in the placebo and vitamin D groups, 
respectively (p = 1.00).
Discussion
A randomized clinical trial (RCT) was 
designed to explore the effect of intramuscular 
high dose of vitamin D on HRQOL, in 
hospitalized AECOPD patients with coexisting 
p-valueVitamin D group (n = 30)Placebo group (n = 32)Variable
0.38LABA: 4 (13.33%)LABA: 7 (21.88%)
Drug
0.46ICS: 8 (26.67%)ICS: 9 (28.13%)
0.31LABA+ICS: 24 (80%)LABA+ICS: 22 (68.75%)
0.60LAMA: 17 (56.67%)LAMA: 16 (50%)
0.80Theophylline: 4 (13.33%)Theophylline: 5 (15.63%)
0.66Acetylcysteine: 9 (30%)Acetylcysteine: 8 (25%)
0.42Statin: 5 (16.67%)Statin: 8 (25%)
0.86**5 (4,6)**5 (4,6)Morisky adherence score
0.82*10.82 ± 3.73*11.01 ± 2.99Vitamin D (ng/mL)
0.628.66 ± 2.698.33 ± 2.23WBC cont × 103(cell/μL)
0.89**9.2 (8.75, 9.45)**9.1 (8.65, 9.40)Calcium (mg/dL)
0.39**2.7 (3.1, 3.75)**3.2 (2.95, 3.45)Phosphor (mg/dL)
0.13*85.06 ± 8.37*81.68 ± 8.78SGRQ (Symptom)
0.13**85.66 (71.20, 87.16)**78.96 (63.97, 85.81)SGRQ (Activity)
0.63*55.98 ± 14.12*54.15 ± 15.33SGRQ (Impact)
0.31*67.99 ± 10.67*64.97 ± 12.28SGRQ (Total)
0.31
Grade 3: 6 (20%)Grade 3: 10 (31.25%)
Dyspnea scale (mMRC)
Grade 4: 24 (80%)Grade 4: 22 (68.75%)
*Data has been presented as mean ± SD. **Data has been presented as median (interquartile range 25th, 75th percentiles), BMI: Body Mass 
Index, IHD: Ischemic Heart Disease, HF: Heart Failure LABA: Long Acting Beta 2 Agonist, LAMA: Long-Acting Muscarinic Antagonist, 
ICS: Inhaled Cortico-Steroid, SGRQ: ST George’s Respiratory Questionnaire, mMRC: modified Medical Research Council.
Table 1. Continued.
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vitamin D deficiency. This study was different in 
some aspects from previous trials. Firstly, most 
of the previous studies have focused on clinical 
outcomes such as exacerbation rate, readmission, 
exercise capacity, and mortality rate (22, 24-
26 and 28) and also data about the effect of 
vitamin D on health related quality of life using 
a comprehensive questionnaire such as SGRQ 
are lacking. Secondly, in many of the previous 
researches, patients with sufficient levels of 
vitamin D were also included in the study (21, 
23-25) Thirdly, in these studies, patients with 
stable disease were also recruited (22, 24-26) 
and trials on AECOPD population are lacking. 
Lastly, most of the previous studies have used 
frequently administered oral dosing of vitamin D 
(21, 23 and 25-28), in which, patient compliance 
might have affected their final findings. 
In our RCT, the prevalence of VDD among 
AECOPD patients was high (89.40%) at 
baseline. Vitamin D levels were well-correlated 
with disease severity and this was in accordance 
with recent meta-analysis in COPD patients 
reported in 2016 (10). Our study showed 
significant impaired quality of life in AECOPD 
patients, demonstrated by overall high SGRQ 
total scores, which was correlated with disease 
severity (r = 0.91, p < 0.001). This was confirmed 
by previous reports (11). 
In vitamin D group, rapid normalization 
of vitamin D levels with a recommended high 
dose of vitamin D 300,000 IU (29) resulted in 
significant statistical improvement in HRQOL 
of the patients, by day 30 [p = 0.0003, (CI 
-2.96, -0.94)] and day 120 [p = 0.0001, (CI 
-6.11, -3.23)]; however, this improvement was 
not considered clinically significant by Day 30 
and reached clinically significant level by day 
120, since mean difference of 4.67 in between 
groups comparison exceeded the minimum 
clinically important difference of 4 units (30) 
. Improvement in other clinical end points 
such as mMRC (p = 0.48), LOS (p = 0.36), 
rehospitalization (p = 0.33), and mortality rates 
(p = 1.00) were not statistically significant. 
The data about vitamin D supplementation 
in COPD patients have resulted in controversial 
but promising findings (20). Some studies have 
reported no beneficial effect for vitamin D 
on exercise capacity of the patients including 
6-minute walking test, saturation of oxygen 
during exercise, COPD assessment test score, 
and pulmonary function test (22, 24). On the 
other hand, beneficial effect of vitamin D 
supplementation has been documented in several 
studies. In a study by Lehouk et al. vitamin 
D supplementation in 30 participants with 
coexisting VDD showed a significant reduction 
Figure 2. Change in mMRC score during study period in vitamin D and Placebo groups.
The mMRC scores at baseline in placebo and vitamin D groups were not statistically different 
(p = 0.31) (Table 1). By day 30 change in mMRC scores were 0.97 ± 0.78 and 1.13 ± 0.82 in 
placebo and vitamin D groups respectively (p = 0.44). By day 120, the change in mMRC 
scores were 1 ± 0.76 and 1.27 ± 0.78 in placebo and vitamin D groups respectively (p = 
0.17). There is no statistically significant difference in between group comparison. Change in 
mMRC score during study period in vitamin D and placebo groups was showed in Figure 2.  
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in exacerbations; however, pulmonary function, 
hospitalization and mortality did not significantly 
differ between study groups (31). In a study by 
Rezk et al. carried out on COPD patients with 
VDD, a significant improvement in dyspnea 
scale (mMRC), physical performance, maximum 
voluntary ventilation, maximum inspiratory 
pressure, and maximum expiratory pressure, 
coupled with a decrease in disease exacerbations 
and CRP a year after vitamin D replacement 
were reported. However, the FEV1 and FVC 
did not differ significantly (28). In another study 
by Martineau et al. vitamin D was protective 
against moderate or severe exacerbations in 
COPD patients with VDD (26). In an RCT by 
Zendedel et al. vitamin D supplementation 
resulted in significant improvement in FEV1 
and significant decrease in the number of COPD 
exacerbations of COPD patients (25). It is also 
shown that vitamin D supplementation can 
result in significantly greater improvements in 
inspiratory muscle strength and maximal oxygen 
uptake. However, improvements in quadriceps 
strength or six minutes walking distance test 
could not reach a significantly improved level 
(27).
Based on our literature review, the data about 
the effect of vitamin D on the quality of life of the 
COPD patients, determined by a comprehensive 
tool such as SGRQ, were limited to one study by 
Bjerk et al. It was performed on Caucasian male 
subjects. The results revealed no improvements 
in HRQOL (SGRQ) and physical activity of the 
study patients. This study has several limitations 
such as small sample size (n = 36) and a short 
follow up period (6 weeks). The differences 
between this and our study were vitamin D 
dosing (multiple low oral dosing versus single 
high intramuscular dosing of vitamin D), 
study subjects (stable COPD versus AECOPD 
patients), and inclusion criteria (which was not 
included vitamin D deficiency) (23).
 In a recent study on asthmatic patients by 
Rajanandh et al. vitamin D supplementation 
(1000 IU/day) resulted in statistical as well 
as clinical improvement in all domains of the 
SGRQ including symptom score, impact score, 
activity (from day 30 onward), and total score 
by day 180 (32). The results were in agreement 
with our study by the difference in the study 
populations.
In the interpretation of the results obtained 
in our study and their comparison with those 
described in the previous reports, methodological 
and clinical differences including dose and 
route of the vitamin D administration, disease 
related factors, genetic features of the study 
population, inclusion and exclusion criteria 
and characteristics of the patients should be 
acknowledged.
Limitations of the study
Patients included in this study were AECOPD 
patients with concomitant VDD; therefore, our 
findings may not be generalized to all AECOPD 
patients. A relatively short follow up period of 
120 days was considered in this study, which 
may not have been long enough to document 
the delayed clinical outcomes resulted by the 
intervention.
Table 2. Differences between baseline and the 30th and 120th days of SGRQ scores and its components in the study groups.
SGRQ 
component
By day 30 By day 120
Placebo Vitamin D p-value Placebo Vitamin D p-value
Symptom 
score 10.71 ± 6.44 15.18 ± 8.85 0.050 12.26 ± 7.81 19.45 ± 8.94 0.001
*
Activity score 1.88 ± 3.73 4.11 ± 3.43 0.008* 2.69 ± 3.96 8.11 ± 6.13 0.001*
Impact score 2.61 ± 3.20 3.77 ± 3.82 0.40 2.13 ± 4.39 5.76 ± 4.62 0.007*
Total score 3.73 ± 1.84 5.69 ± 2.13 0.0003* 3.99 ± 2.19 8.66 ± 3.32 0.0001*
*Significant improvement in vitamin D group versus placebo (p < 0.05)
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Conclusion
HRQOL in hospitalized AECOPD patients 
with concomitant deficient levels of vitamin 
D was significantly impaired. Vitamin D 
replacement with a single parenteral injection 
could be an effective intervention to improve 
patients’ HRQOL; however improvement 
in other clinical outcomes such as LOS, 
rehospitalization and mortality rates were not 
achieved. Further studies with a longer follow 
up period are recommended.
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